Mazzuca F., Botticelli A., Mazzotti E., La Torre M., Borro M., Marchetti L., et al.
EURASIAN JOURNAL OF MEDICINE, cilt.48, ss.10-14, 2016 (ESCI İndekslerine Giren Dergi)
EURASIAN JOURNAL OF MEDICINE
Objective: Third-generation aromatase inhibitors (AI) are potent suppressors of aromatase activity. The aim of this study was to measure the incidence of adverse effects in breast cancer patients treated with AI-based adjuvant therapy and the relationship with the CYP19A1 genotypes.